Quince therapeutics announces the lancet neurology publication of phase 3 attest clinical trial data evaluating erydex for the treatment of ataxia-telangiectasia (a-t)

South san francisco, calif.--(business wire)---- $qncx #biotech--quince therapeutics, inc. (nasdaq: qncx), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced the online publication of data in the lancet neurology from its phase 3 attest (ataxia-telangiectasia trial with the erydex system; #iedat-02-2015/nct02770807) clinical trial evaluating the safety and efficacy of its lead asset, erydex (dexamethasone sodium phosph.
QNCX Ratings Summary
QNCX Quant Ranking